International journal of urology : official journal of the Japanese Urological Association · 2026
Effect of Neoadjuvant Chemo-Hormonal Therapy on Reducing Recurrence in Patients With Very High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koyama Yuri, Morizane Shuichi, Moriyasu Emika, Hoshino Takahiro, Yamamoto Atsushi, Omatsu Rumiko, Yamane Hiroshi, Makishima Karen, Nishikawa Ryoma, Kimura Yusuke, Yamaguchi Noriya, Hikita Katsuya, Umekita Yoshihisa, Takenaka Atsushi
Аннотация
OBJECTIVE: In this study, we evaluated the efficacy of neoadjuvant chemo-hormonal therapy before robot-assisted radical prostatectomy in patients with very high-risk prostate cancer.
METHODS: Patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy with extended lymph node dissection at our hospital between January 2017 and September 2024 were included. We retrospectively compared the biochemical progression-free survival rates between patients treated with (n = 22) and without (n = 26) neoadjuvant chemo-hormonal therapy. The neoadjuvant chemo-hormonal therapy group received seven-month hormonal therapy (androgen deprivation therapy plus bicalutamide) with 70 mg/m2 docetaxel (every three weeks over three cycles). Data were analysed using Easy R, Kaplan-Meier method, log-rank test, and Cox proportional hazards model (significance p < 0.05).
RESULTS: Patient backgrounds showed significant inter-group differences in age (p = 0.010) and initial prostate-specific antigen levels (p = 0.004), but not in clinical T stage (p = 0.355), clinical N stage (p = 0.081), biopsy Gleason score (p = 0.485), or positive biopsy cores (p = 0.105). Despite the less favorable patient backgrounds in the neoadjuvant chemo-hormonal therapy group, 3-year biochemical progression-free survival rates were significantly higher (70.6% vs. 35.3%; p = 0.039). Using multivariate analysis, neoadjuvant chemo-hormonal therapy significantly reduced biochemical recurrence (hazard ratio, 0.34; 95% confidence interval: 0.14-0.83, p = 0.018).
CONCLUSION: Neoadjuvant chemo-hormonal therapy before robot-assisted radical prostatectomy resulted in favorable biochemical progression-free survival rates in patients with very high-risk prostate cancer. This result suggests that this therapeutic approach has potential for becoming a new standard of care.
METHODS: Patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy with extended lymph node dissection at our hospital between January 2017 and September 2024 were included. We retrospectively compared the biochemical progression-free survival rates between patients treated with (n = 22) and without (n = 26) neoadjuvant chemo-hormonal therapy. The neoadjuvant chemo-hormonal therapy group received seven-month hormonal therapy (androgen deprivation therapy plus bicalutamide) with 70 mg/m2 docetaxel (every three weeks over three cycles). Data were analysed using Easy R, Kaplan-Meier method, log-rank test, and Cox proportional hazards model (significance p < 0.05).
RESULTS: Patient backgrounds showed significant inter-group differences in age (p = 0.010) and initial prostate-specific antigen levels (p = 0.004), but not in clinical T stage (p = 0.355), clinical N stage (p = 0.081), biopsy Gleason score (p = 0.485), or positive biopsy cores (p = 0.105). Despite the less favorable patient backgrounds in the neoadjuvant chemo-hormonal therapy group, 3-year biochemical progression-free survival rates were significantly higher (70.6% vs. 35.3%; p = 0.039). Using multivariate analysis, neoadjuvant chemo-hormonal therapy significantly reduced biochemical recurrence (hazard ratio, 0.34; 95% confidence interval: 0.14-0.83, p = 0.018).
CONCLUSION: Neoadjuvant chemo-hormonal therapy before robot-assisted radical prostatectomy resulted in favorable biochemical progression-free survival rates in patients with very high-risk prostate cancer. This result suggests that this therapeutic approach has potential for becoming a new standard of care.